Burelle SA is a France-based holding company active in three areas: Industry and Services, through its subsidiary Compagnie Plastic Omnium SA, investment in other businesses through Burelle Participations and Real Estate, through Sofiparc. Compagnie Plastic Omnium SA, operates through two segments. It specializes in the manufacture of automobile plastic body parts, fuel and pollution control and produces waste containers (waste management systems) and urban/street furniture, as well waste management services. Sofiparc SAS, a wholly owned subsidiary of the Company, manages an office complex in Levallois, and land in Lyon and its Region. Burelle Participations SA, Burelle's wholly owned subsidiary, is an investment company focusing on investment in medium-sized companies through minority or majority interest holdings. The Company is present in Europe, North America, South America, South Africa and Asia....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 16 May 2026
2022-05-05 09:34:00 Thursday ET

Corporate payout management This corporate payout literature review rests on the recent survey article by Farre-Mensa, Michaely, and Schmalz (2014). Out
2018-10-05 10:38:00 Friday ET

A 7-year $1.3 billion hedge fund manager Chelsea Brennan shares her investment advice. Her advice encompasses several steps toward better financial literacy
2018-05-04 06:29:00 Friday ET

Commerce Secretary Wilbur Ross suggests that 5G remains a U.S. top technology priority in light of the telecom merger proposal between Sprint and T-Mobile a
2020-05-05 09:31:00 Tuesday ET

Our fintech finbuzz analytic report shines fresh light on the fundamental prospects of U.S. tech titans Facebook, Apple, Microsoft, Google, and Amazon (F.A.
2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be
2018-05-29 11:40:00 Tuesday ET

America and China, the modern world's most powerful nations may stumble into a **Thucydides trap** that Harvard professor and political scientist Graham